trending Market Intelligence /marketintelligence/en/news-insights/trending/CGfnQQ4IFtvHCPG0bAaBxA2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Intercept seeks EU approval for liver disease drug Ocaliva


Needham & Company is Now Available in the S&P Global Market Intelligence Aftermarket Research Collection


Banking Essentials Newsletter - February Edition


Message in a (Word)Cloud

Six trends shaping the industries and sectors we cover in 2021

Intercept seeks EU approval for liver disease drug Ocaliva

Intercept Pharmaceuticals Inc. is seeking EU approval to market Ocaliva as a treatment for nonalcoholic steatohepatitis, a fatal liver disease.

The company's application with the European Medicines Agency is based on a phase 3 trial, called Regenerate, wherein the drug improved patients' fibrosis without worsening the symptoms of nonalcoholic steatohepatitis.

The New York-based biotech also said in a Dec. 13 press release that it expects an advisory committee meeting with the U.S. Food and Drug Administration on April 22, 2020, regarding Ocaliva's label expansion. The regulator was expected to make a decision on Intercept's U.S. application by March 26, 2020, but will now likely push that forward, Intercept said.

Ocaliva is also known as obeticholic acid.